logo-loader

Zelda Therapeutics brings medical cannabis trials to Proactive's CEO Sessions

Published: 08:38 27 Oct 2017 AEDT

Zelda Therapeutics at the Proactive's CEO Sessions
Dr. Stewart Washer, managing director, will present at Proactive's CEO Sessions

Zelda Therapeutics Ltd (ASX:ZLD) is developing a range of cannabinoid-based formulations to treat medical conditions, and recently sponsored an observation autism trial in Chile.

The trial demonstrated successful results for treating the core symptoms of autism with medicinal cannabis extracts that Zelda is planning on taking into clinical trials.

Results showed that in a cohort of 21 patients, cannabis extracts were significantly more effective than conventional medicines used, including atypical antipsychotics, and these extracts were well tolerated by the patients overall.

Find out more from Dr. Stewart Washer at Proactive's CEO Sessions.

Click below to register by email

- Melbourne: Tuesday 14th November.
- Sydney: Wednesday 15th November.
- Email Pauline here.
- Call office on (02) 9280 0700.

Presenter list

- Zelda Therapeutics (ASX:ZLD): Dr. Stewart Washer
- Thred Ltd (ASX:THD): Geoff Marshall
- De Grey Mining (ASX:DEG): Simon Lill
- Peninsula Energy (ASX:PEN): David Coyle
- Aspire Mining (ASX:AKM): David Paull

 

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

12 hours, 14 minutes ago